Back

On-label versus off-label direct oral anticoagulant dosing patterns and associated outcomes in atrial fibrillation: a real-world cohort analysis

28 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: real-world outcomes and risk Stroke in Atrial Fibrillation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Giuseppe Patti

University of Eastern Piedmont, Novara (Italy)

5 More presentations in this session

Presentation thumbnail
Impact of frailty on in-hospital and long-term outcomes after atrial fibrillation ablation in patients aged ≥75 years
Doctor H. Altamimi (Concord West, AU)
Abstract Slides Video
Presentation thumbnail
Long-term ozone exposure and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation: a nationwide cohort study
Doctor C. Wang (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes following atrial fibrillation diagnosis in routine practice: a nationwide cohort study in Sweden
Professor J. Engdahl (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Prognostic associations of major bleeding in anticoagulated patients with atrial fibrillation after TAVI: a post hoc analysis of the ENVISAGE-TAVI AF trial
Doctor G. Dangas (New York, US)
Abstract Slides Video
Presentation thumbnail
Clinical impact of atrial fibrillation on cardiac parameters and long-term outcomes in patients with transthyretin amyloid cardiomyopathy in the era of disease-modifying therapy
Doctor S. Yamauchi (Okayama, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: real-world outcomes and risk

The Event

Event poster

ESC Congress 2026

28 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe
14 April 2026
thumbnail
Congress Presentation
Plasma apixaban levels and thrombin generation assay in patients with atrial fibrillation with dose reduction criteria of apixaban
2 September 2024
thumbnail
Congress Presentation
Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease
31 August 2025
thumbnail
Congress Presentation
Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources